Aixial Group Migrates Specific Clinical Data Portfolio Onto Medidata Platform to Create a Single Source of Truth and Accelerate Database Lock
Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced a new project with Aixial Group, a contract research organization (CRO), to streamline the execution of studies and achieve database lock faster. Aixial Group will migrate clinical data from one of its business units onto the Medidata Platform to create a Single Source of Truth (SSOT) that enables study teams to support patient data privacy, monitor throughout the study to keep patients safe, and make better-informed decisions.
"Aixial Group offers our trial sponsors the reliability and flexibility at scale they need to accelerate their clinical research programs and deliver results fast,” said Jonas Möller, managing director, Aixial Group. “Consolidating clinical data onto the Medidata Platform will power the experience and expertise of our teams to deliver this superior service for our customers,” concluded Tim Corbett-Clark, chief technology officer, Aixial Group.
“This engagement enables Aixial Group to provide increased consistency and control within their operations, helping them further excel in the global clinical research market,” said Janet Butler, executive vice president, head of global sales, Medidata. “Medidata Rave EDC will enhance their support for studies of any size, length, or complexity and translate their productivity into more patients accessing better treatments sooner.”
About Medidata
Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 34,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across approximately 2,200 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.
About Dassault Systèmes
Dassault Systèmes is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all – consumers, patients and citizens. Dassault Systèmes brings value to more than 350,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.com.
© Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries. All other trademarks are owned by their respective owners. Use of any Dassault Systèmes or its subsidiaries trademarks is subject to their express written approval.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240903518594/en/
Contacts
Medidata PR
Medidata.PR@3ds.com
Analyst Relations
Medidata.AR@3ds.com - medidata.AR@3ds.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Det-Tronics Acquires Optronics8.1.2026 14:28:00 EET | Press release
Det-Tronics, a global leader in fire and gas safety systems, has acquired Optronics, a Norway-based company that specializes in optical gas detection technologies. Det-Tronics is part of Spectrum Safety Solutions that is based in Stamford, CT. Optronics, founded in 2018, is a technology leader in high-end optical gas detection products and solutions for energy, marine and industrial applications. Optronics has a strong record of innovation, bringing leading products and expert solutions to market for its customers. (www.optronics-technology.com) “Det-Tronics’ strategy is built on growth, innovation and quality. Optronics and Det-Tronics are a perfect fit to grow our businesses, drive new innovations and lead the market with high quality and reliable products and solutions,” noted Johannes Mario Kahlert, President of Det-Tronics. “We are very excited for the path ahead to deliver outstanding value to our customers together.” “Optronics is an innovation leader in high-end optical gas det
Virometix AG Announces Positive Data from Phase 1 Trial of V-212, a Fully Synthetic, Serotype-Independent Vaccine Development Candidate for the Prevention of Pneumococcal Disease8.1.2026 14:00:00 EET | Press release
Virometix AG, a clinical-stage biotechnology company pioneering fully synthetic vaccines, today announced positive topline data from the Company’s Phase 1 trial of its lead asset V-212, a serotype-independent pneumococcal vaccine candidate, in development for the prevention of pneumococcal disease caused by Streptococcus pneumoniae (Spn) infections. The study evaluated safety and immunogenicity in healthy volunteers, with data demonstrating an excellent safety profile and robust immune responses across all three target antigens in the vaccine. Results support further development of V-212 independently and in combination with an approved PCV. “With the significant need for an effective serotype-independent vaccine, we are pleased to report positive results, which highlight the excellent safety profile and immunogenicity of V-212 and, more broadly, validate our Synthetic Virus-Like Particle (SVLP) platform approach for the development of broad-spectrum, self-adjuvanted vaccines with high
Abbelight Announces Successful Series B Investment led by AVANT BIO to Accelerate Imaging Innovation and Scale Adoption Across a Broader Customer Base8.1.2026 13:36:00 EET | Press release
Abbelight, a global leader and a pioneer in super-resolution microscopy end-to-end solutions, today announced a successful Series B financing round led by AVANT BIO, a growth equity firm focused on enabling technologies shaping tomorrow’s therapeutics. “With a decade of experience in the Life Science Research market, Abbelight has been transforming the way scientists see, quantify, and interpret all kinds of complex intracellular mechanisms. It’s now time to tailor our cutting-edge imaging toolbox to also address new key verticals, such as single cell phenotyping and mechanisms of action validation for drug discovery”, says Nicolas Bourg CTO and co-founder. “Big things happen at the nanoscale - and Abbelight enables researchers to visualize precise sub-cellular structures like never before”, said Daniella Kranjac, Founding General Partner at AVANT BIO. “Their breakthroughs in super-resolution microscopy and sample-to-insight workflows embody the kind of enabling technologies that accel
FGS Global launches 2026 Radar Report: "A Rewired World"8.1.2026 12:00:00 EET | Press release
The post-war global order is fragmenting into spheres of influence as strongman leadership and transactional relationships replace multilateral cooperation, according to FGS Global's Radar 2026 report released today. FGS Global’s Radar is based on 175 in-depth interviews with senior global leaders and policy experts from the worlds of business, politics, academia and media and wide ranging, nationally representative polling of approximately 20,000 people across the US, Canada, the member countries of the European Union and Japan. We are in a Rewired World reshaped by the collapse of multilateral consensus and the rise of strongman leadership over weakened institutions. US-China competition is intensifying across trade, technology and space while traditional alliances fracture. At the same time, AI-driven disruption is accelerating change, populist disruptors are challenging established systems and influence is atomizing as mainstream media and political parties lose ground. The implica
GEOLOG Acquires Quad Ltd and QO Inc. to Enhance Global Wellsite Geology and Pore Pressure Services8.1.2026 12:00:00 EET | Press release
GEOLOG International B.V. (“GEOLOG” or the “Company”), a leading independent provider of wellsite geosciences, drilling solutions and surface logging services to the energy industry, today announced the successful acquisition of Quad Ltd and QO Inc. (together, “Quad”). Quad is a long-standing provider of wellsite and operations geologists, along with advanced pore pressure and fracture gradient analysis services. This strategic bolt-on acquisition significantly enhances GEOLOG’s portfolio of advanced subsurface and drilling support services and solidifies its operational presence globally. GEOLOG and Quad have a history of successful collaboration on numerous international projects, serving a broad spectrum of energy clients. Integrating Quad’s highly experienced personnel and specialized technical capabilities will strengthen GEOLOG’s capacity to support clients in complex drilling environments, spanning from exploration through development and production phases. “Quad has been a trus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom